

CLAIM SUMMARY DOCUMENT:

C1

1. (Currently Amended) ~~An~~ A synergistic inhibitor composition of *Helicobacter pylori* adhesion in the gastrointestinal tract of a mammal, consisting essentially of ~~including humans, comprising~~ (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated *Helicobacter pylori* urease, wherein said IgY antibodies are capable of specifically binding to the adhesion portion of *Helicobacter pylori* urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H₂ blockers and proton pump inhibitors.

2. (Original) The inhibitor composition according to Claim 1, wherein the IgY antibodies are isolated and purified antibodies.

3. (Currently Amended) A pharmaceutical composition for preventing and/or treating a disease caused by or associated with *Helicobacter pylori* in a mammal, consisting essentially of: ~~including humans, comprising~~

a pharmaceutically effective amount of ~~the~~ a synergistic inhibitor composition consisting essentially of comprising (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated *Helicobacter pylori* urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H₂ blockers and proton pump ~~inhibitors, inhibitors:~~ and

(05/03)

Attorney's Docket No. 011900-310Application Serial No. 09/903,734

Page 3

a pharmaceutically acceptable carrier or diluent.

C1
cont'

4. (Original) The pharmaceutical composition according to Claim 3, wherein the IgY antibodies are isolated and purified antibodies.

C2

5. (Currently Amended) A method for inhibiting *Helicobacter pylori* adhesion in a mammal including humans, comprising orally administering to the mammal an inhibitor composition in an effective amount for inhibiting *Helicobacter pylori* adhesion, which composition ~~comprises~~ consists essentially of (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated *Helicobacter pylori* urease, wherein said IgY antibodies are capable of specifically binding to the adhesion portion of *Helicobacter pylori* urease in the gastrointestinal tract of the mammal, and (2) at least one agent selected from H₂ blockers and proton pump inhibitors ~~an inhibitor of gastric acid secretion.~~

6. (Currently Amended) A method for preventing and/or treating a disease caused by or associate with *Hekocobacter pylori* in a mammal including humans, comprising orally administering to the mammal an inhibitor composition in an effective amount for preventing or treating the disease, which composition ~~comprises~~ consists essentially of (1) IgY antibodies obtained from at least one chicken egg laid by a hen which has been immunized with an antigenically effective amount of an isolated *Heliobactor pylori* urease,

(05/03)

Attorney's Docket No. 011900-310Application Serial No. 09/903.734

Page 4

CF
cont

wherein said IgY antibodies are capable of specifically binding to the adhesion portion of
Helicobacter pylori urease in the gastrointestinal tract of the mammal, and (2) at least one
agent selected from H₂ blockers and proton pump inhibitors ~~an inhibitor of gastric acid~~
secretion.

C3

5/ (New) The inhibitor composition according to Claim 1, wherein the mammal is a
human.

6/ (New) The pharmaceutical composition according to Claim 3, wherein the
mammal is a human.

(05/03)